David A. Siegel Zentalis Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,275,914 shares of ZNTL stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,275,914
Previous 842,600
51.43%
Holding current value
$1.99 Million
Previous $1.34 Million
10.53%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ZNTL
# of Institutions
124Shares Held
60.6MCall Options Held
0Put Options Held
22K-
Matrix Capital Management Company, LP Waltham, MA14MShares$21.8 Million8.42% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$7.52 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$5.42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.5 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$4.37 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $88.9M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...